TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24176144

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 1502
Study: 22669291

Group type: EXPERIMENTAL
Intervention: MK-7246 in UGT2B17*2/*2 carriers
Number of subjects: 0

Group type: COMPARATOR
Intervention: MK-7246 in UGT2B17*1/*1 wild-type genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M3-to-MK-7246 AUC ratio in UGT2B17*2/*2 carriers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apparent half-life of MK-7246
Number of subjects: 0
Study: 19415540

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 115
Study: 17330306

Group type: EXPERIMENTAL
Intervention: Arthritis self-management program in primary care
Number of subjects: 31
Study: 15222284

Group type: EXPERIMENTAL
Intervention: Mosaic bioprosthesis
Number of subjects: 139

Group type: COMPARATOR
Intervention: Perimount bioprosthesis
Number of subjects: 139
Study: 11123737

Group type: EXPERIMENTAL
Intervention: Sublingual morphine 0.1 mg x kg(‐1)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous morphine 0.1 mg x kg(‐1)
Number of subjects: 29
Study: 9882058

Group type: EXPERIMENTAL
Intervention: Mepitel dressing
Number of subjects: 76

Group type: COMPARATOR
Intervention: Flamazine treatment (standard silver sulfadiazine cream)
Number of subjects: 76
Study: 8031483

Group type: EXPERIMENTAL
Intervention: Dentrust (manual toothbrush)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Crest Complete (manual toothbrush)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Interplak (mechanical toothbrush)
Number of subjects: 25
Study: 2465709

Group type: EXPERIMENTAL
Intervention: 1.5 mg hydromorphone with 1/200,000 epinephrine (N = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.5 mg hydromorphone alone (N = 15)
Number of subjects: 30
Study: 31856912

Group type: EXPERIMENTAL
Intervention: Irinotecan dose-escalated FOLFIRI according to UGT1A1 genotyping plus 120 mg regorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: 120 mg regorafenib alone
Number of subjects: 0
Study: 27033552

Group type: EXPERIMENTAL
Intervention: No-ventilation group (intubation tube detached from the ventilator)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low tidal volume group (continuous low tidal volume ventilation)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Continuous 10 cm H2O positive airway pressure
Number of subjects: 47

Group type: COMPARATOR
Intervention: Patients without cardiopulmonary bypass (referral group)
Number of subjects: 47
Study: 25557853

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg once a day for a month
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paroxetine 20 mg once a day for a month
Number of subjects: 80
Study: 24176253

Group type: EXPERIMENTAL
Intervention: Housing First with Intensive Case Management (HF-ICM)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Housing First with Assertive Community Treatment (HF-ACT)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Congregate housing with support
Number of subjects: 497

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 497
Study: 21235425

Group type: EXPERIMENTAL
Intervention: Median or lateral umbilicus ligament covering the internal hernia opening region after laparoscopic purse‐string knot
Number of subjects: 428

Group type: COMPARATOR
Intervention: Laparoscopic purse‐string knot closing the internal hernia opening only
Number of subjects: 428
Study: 19755362

Group type: EXPERIMENTAL
Intervention: Case management by health care assistants
Number of subjects: 626

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 626
Study: 17225705

Group type: EXPERIMENTAL
Intervention: Surgical resection for stages I through IIIA non-small cell carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodality approach including radiotherapy, chemotherapy, and palliative care for advanced non-small cell carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy (combined with radiotherapy for limited disease) for small cell carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study: 15065952

Group type: EXPERIMENTAL
Intervention: Written disclosure condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 11265023

Group type: EXPERIMENTAL
Intervention: PolyHeme (up to 20 units)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRBCs
Number of subjects: 0
Study: 9778003

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inhalation of salbutamol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined treatment of salbutamol and intravenous lidocaine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7980747

Group type: EXPERIMENTAL
Intervention: Empirical H2-blocker treatment (group 2)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Prompt endoscopy (group 1)
Number of subjects: 414
Study: 3136677

Group type: EXPERIMENTAL
Intervention: alfentanil 500 micrograms and midazolam 5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: alfentanil 500 micrograms alone
Number of subjects: 100
Study: 31238011

Group type: EXPERIMENTAL
Intervention: High-sodium meal (HSM; 1495 mg Na+)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-sodium meal (LSM; 138 mg Na+)
Number of subjects: 20
Study: 30641326

Group type: EXPERIMENTAL
Intervention: Sustained inflation (15 seconds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine UK practice (five inflations lasting 2 to 3 seconds)
Number of subjects: 0
Study: 27572063

Group type: EXPERIMENTAL
Intervention: Magnetic Endoscopic Imaging (MEI)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard Colonoscopy (without MEI)
Number of subjects: 246
Study: 25909681

Group type: EXPERIMENTAL
Intervention: Fenspiride (80 mg thrice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (antibacterial preparations, topical decongestants, glucocorticoids)
Number of subjects: 80
Study: 22571977

Group type: EXPERIMENTAL
Intervention: DaTscan imaging
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group without imaging
Number of subjects: 267
Study: 21888757

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 110 μg once daily for 2 weeks
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 363
Study: 17607120

Group type: EXPERIMENTAL
Intervention: Docetaxel 35 mg/m2 IV on days 1, 8, and 15, and cisplatin 80 mg/m2 IV on day 15, every 4 weeks for four cycles
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 IV plus cisplatin 80 mg/m2 IV on day 1 every 3 weeks for four cycles
Number of subjects: 27
Study: 16305726

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3-Impact Powder)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Omega-6 fatty acids (6-Impact Powder)
Number of subjects: 31
Study: 11810600

Group type: EXPERIMENTAL
Intervention: CVC removal
Number of subjects: 21
Study: 9866064

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin from day 2 of the cycle through pregnancy testing
Number of subjects: 36

Group type: COMPARATOR
Intervention: No aspirin (Control)
Number of subjects: 36
Study: 7637874

Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha 2-adrenergic antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (postoperative intravenous)
Number of subjects: 0
Study: 10295702

Group type: EXPERIMENTAL
Intervention: Procedural information (5-min tape recorded message)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sensory information (5-min tape recorded message)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sensory information
Number of subjects: 30
Study: 183943

Group type: EXPERIMENTAL
Intervention: Propranolol (180 and 360 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 90
Study: 29392960

Group type: EXPERIMENTAL
Intervention: IL2/IFN/BEV
Number of subjects: 118

Group type: COMPARATOR
Intervention: IL2/IFN
Number of subjects: 118
Study: 27185571

Group type: EXPERIMENTAL
Intervention: QGE031 (240 mg every 2 weeks for 10 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Omalizumab
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 23890196

Group type: EXPERIMENTAL
Intervention: Autologous serum diluted with sodium hyaluronate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Autologous serum diluted with saline
Number of subjects: 26
Study: 22715966

Group type: EXPERIMENTAL
Intervention: MoVo-LISA intervention group
Number of subjects: 220
Study: 20013579

Group type: EXPERIMENTAL
Intervention: Early minimal enteral feeding (MEF) initiated at <= 5 days; median age: 2 days (range: 1 to 5 days)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Delayed minimal enteral feeding (MEF) initiated at >= 6 days; median age: 7 days (range: 6 to 14 days)
Number of subjects: 84
Study: 18550253

Group type: EXPERIMENTAL
Intervention: Zirconia-based all-ceramic fixed partial dentures with inlay retainers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Different resin cements used for adhesion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plaque accumulation on abutment teeth
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative sensitivity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aesthetic and functional performance of FPDs
Number of subjects: 30
Study: 16037180

Group type: EXPERIMENTAL
Intervention: 3 mL of 1.5% lidocaine containing 15 mug of epinephrine IV
Number of subjects: 80

Group type: COMPARATOR
Intervention: 3 mL of saline IV
Number of subjects: 80
Study: 12727307

Group type: EXPERIMENTAL
Intervention: 10 Hz TENS
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 Hz TENS
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High frequency TENS (100 Hz)
Number of subjects: 16
Study: 10759733

Group type: EXPERIMENTAL
Intervention: Topical anaesthetic cream (containing lignocaine and prilocaine) followed by local anaesthetic infiltration
Number of subjects: 53

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 53
Study: 8613046

Group type: EXPERIMENTAL
Intervention: Methotrexate (12.5 mg once weekly for 9 months)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 1358484

Group type: EXPERIMENTAL
Intervention: Subcutaneous bolus injections of 100 micrograms octreotide every 8 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of the same daily dose of octreotide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both bolus and continuous infusion treatment
Number of subjects: 6
Study: 4013628

Group type: EXPERIMENTAL
Intervention: Intercostal block (i.c.b.) and centrally acting analgesics on demand
Number of subjects: 417

Group type: COMPARATOR
Intervention: Centrally acting analgesics alone
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Unilateral i.c.b. following cholecystectomy and choledocholithotomy
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Bilateral i.c.b. given after surgery through a midline incision
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Age-dependent analgesic demand
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Smokers receiving i.c.b.
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Duration of treatment with centrally acting analgesics
Number of subjects: 417
Study: 31584141

Group type: EXPERIMENTAL
Intervention: Mentoring-based intervention (Campus Connections)
Number of subjects: 238
Study: 28857909

Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training)
Number of subjects: 26

Group type: COMPARATOR
Intervention: MICT (moderate-intensity continuous training)
Number of subjects: 26
Study: 27820648

Group type: EXPERIMENTAL
Intervention: Combined treatment of traditional Chinese medicine and Western medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine treatment
Number of subjects: 60
Study: 23149467

Group type: EXPERIMENTAL
Intervention: Palmar percutaneous approach
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dorsal limited approach
Number of subjects: 76
Study: 22895080

Group type: EXPERIMENTAL
Intervention: Low glycinin soymilk (LGS, 49.5% β‐conglycinin/6% glycinin)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Conventional soymilk (S, 26.5% β‐conglycinin/38.7% glycinin)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bovine milk (M, 0% β‐conglycinin/0% glycinin)
Number of subjects: 64
Study: 20816841

Group type: EXPERIMENTAL
Intervention: Testosterone with low cortisol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone with high cortisol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone after social threat (social defeat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High cortisol with higher testosterone
Number of subjects: 0
Study: 17224178

Group type: EXPERIMENTAL
Intervention: Daily injectable recombinant GH for 9 months
Number of subjects: 2006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2006
Study: 16125525

Group type: EXPERIMENTAL
Intervention: Fluvastatin (Flu) administered for 6 weeks
Number of subjects: 0
Study: 12163783

Group type: EXPERIMENTAL
Intervention: C1-inhibitor intravenously in a 1-hr infusion, starting with 6000 IU, followed by 3000 IU, 2000 IU, and 1000 IU at 12-hr intervals
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10357404

Group type: EXPERIMENTAL
Intervention: Combined paclitaxel (50 mg/m2/dose), cisplatin (15 mg/m2/dose), and etoposide (40 mg/m2/dose) administered twice weekly for 3 weeks, repeated every 28 days.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Radiation therapy with or without concomitant 5-fluorouracil after chemotherapy.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 25
Study: 8951506

Group type: EXPERIMENTAL
Intervention: Leflunomide therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active metabolite of leflunomide, A77 1726
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A77 1726
Number of subjects: 0
Study: 1984883

Group type: EXPERIMENTAL
Intervention: Thallium reinjection after stress-redistribution imaging
Number of subjects: 16

Group type: COMPARATOR
Intervention: PET imaging with FDG
Number of subjects: 16
Study: 6189695

Group type: EXPERIMENTAL
Intervention: L-tryptophan (4 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30902911

Group type: EXPERIMENTAL
Intervention: Transversus thoracis muscle plane (TTP) block with 20 mL of either 0.3% or 0.5% ropivacaine bilaterally
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard care (control group, no injections)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Transversus thoracis muscle plane (TTP) block
Number of subjects: 19
Study: 30394494

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (cold therapy with local sterile frozen ice compress)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (conventional sterile compress)
Number of subjects: 100
Study: 26644172

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 22984171

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg BID
Number of subjects: 38

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study: 22113535

Group type: EXPERIMENTAL
Intervention: Nutraceutical-Combined Pill (berberine 500 mg, policosanol 10 mg, red yeast rice 200 mg, folic acid 0.2 mg, coenzyme Q10 2.0 mg, astaxanthin 0.5 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20017910

Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg of ezetimibe plus 160 mg of fenofibrate)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Atorvastatin monotherapy (10 mg)
Number of subjects: 43
Study: 17005079

Group type: EXPERIMENTAL
Intervention: Gutai Decoction (GTD) - Group A (started from the 2nd day of transferring)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Gutai Decoction (GTD) - Group B (started from the 14th day after transferring)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group (no additional GTD treatment)
Number of subjects: 247
Study: 15357626

Group type: EXPERIMENTAL
Intervention: Heberon Alfa R (formulation A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Viraferon (formulation B)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 14
Study: 11132386

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (median total dose of 9.6 mg/kg and 57.9 mg/kg of lumefantrine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Artesunate-mefloquine (12 mg/kg over 3 days and 25 mg/kg)
Number of subjects: 200
Study: 9061388

Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage using Cell Saver
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (patients without autotransfusion)
Number of subjects: 37
Study: 8400342

Group type: EXPERIMENTAL
Intervention: 24 h tube feeding and bag changes (n = 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 48 h tube feeding and bag changes (n = 3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 72 h tube feeding and bag changes (n = 6)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 24 h tube feeding and bag changes (n = 6) in the second study
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 72 h tube feeding and bag changes (n = 6) in the second study
Number of subjects: 20
Study: 3773022

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 10
Study: 28783868

Group type: EXPERIMENTAL
Intervention: Steroid injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27329582

Group type: EXPERIMENTAL
Intervention: rivaroxaban (10 mg/d for 14 days beginning 2-3 hours post-operation)
Number of subjects: 176

Group type: COMPARATOR
Intervention: aspirin (100 mg/d for 3 months beginning 2-3 hours post-operation)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: rivaroxaban
Number of subjects: 176

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 176
Study: 24172937

Group type: EXPERIMENTAL
Intervention: DCD‐training group (aerobic exercise intervention for 16 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: DCD nontraining group (control group)
Number of subjects: 40
Study: 21900536

Group type: EXPERIMENTAL
Intervention: Silicone nasal septal splints with integral airway
Number of subjects: 51

Group type: COMPARATOR
Intervention: Merocel nasal packs
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 20212251

Group type: EXPERIMENTAL
Intervention: Cladribine at 0.12 mg/kg combined with cyclophosphamide at 250 mg/m2 for 3 days intravenously (CC regimen)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Fludarabine at 25 mg/m2 combined with cyclophosphamide at 250 mg/m2 for 3 days intravenously (FC regimen)
Number of subjects: 423
Study: 18492235

Group type: EXPERIMENTAL
Intervention: Proprioceptive balance board training programme (8-week duration, started after usual care)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18249370

Group type: EXPERIMENTAL
Intervention: Cryopreserved seminal plasma
Number of subjects: 168

Group type: COMPARATOR
Intervention: Sodium chloride (placebo)
Number of subjects: 168
Study: 15452834

Group type: EXPERIMENTAL
Intervention: Cisplatin plus paclitaxel (two dose levels)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Cisplatin plus paclitaxel
Number of subjects: 399
Study: 12269651

Group type: EXPERIMENTAL
Intervention: Cyclosporine 2% eyedrops
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 24
Study: 9470082

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 67

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 67
Study: 7943303

Group type: EXPERIMENTAL
Intervention: Muscle biopsy from the vastus lateralis muscle (study B)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control study (study C)
Number of subjects: 8
Study: 3794876

Group type: EXPERIMENTAL
Intervention: Three weekly (tiw) injections of hGH (0.24 IU hGH/kg body weight/wk)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two weekly (biw) injections of hGH (0.24 IU hGH/kg body weight/wk)
Number of subjects: 0
Study: 11728078

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (n 12, 2 x 100 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (n 14, 2 x 300 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n 13)
Number of subjects: 39
Study: 31345626

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (two cycles of cisplatin 50 mg/m2 during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Radiotherapy alone (48.6 Gy in 1.8 Gy fractions)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 660

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 660
Study: 29952013

Group type: EXPERIMENTAL
Intervention: Direct-acting anti-virals
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (no cryoglobulinaemia)
Number of subjects: 182
Study: 27016545

Group type: EXPERIMENTAL
Intervention: Integrated family planning and immunization services
Number of subjects: 1654

Group type: COMPARATOR
Intervention: Standard immunization services only
Number of subjects: 1654
Study: 25026672

Group type: EXPERIMENTAL
Intervention: Integrated Pest Management (IPM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly Application of Pesticide (WAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpesticide Application (Control)
Number of subjects: 0
Study: 21493664

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 18
Study: 20093894

Group type: EXPERIMENTAL
Intervention: Omega-3 supplement (1,200 mg eicosapentaenoic acid and 800 mg docosahexaenoic acid)
Number of subjects: 852

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 852
Study: 17484697

Group type: EXPERIMENTAL
Intervention: Bereavement interventions with children
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Time-sensitive interventions and specific selection criteria
Number of subjects: 13
Study: 16127078

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg administered over 1 h every 8 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged infusions of doripenem
Number of subjects: 0